Research and career
After completing her early medical training in London,she gained membership of the Royal College of Surgeons,who subsequently awarded her a research fellowship. Her research began in 2002 on evaluating photodynamic therapy for prostate cancer. It became the subject of her MD,which was completed in 2007,and led to the first completed randomised trial comparing focal treatment for prostate cancer with active surveillance. Later,she published the first study using magnetic resonance imaging (MRI) to evaluate treatment in early prostate cancer. [1] [2] [3]
Moore started using MRI to detect prostate cancer in men who would not need treatment,and found that if biopsies were performed before MRI scans the images were blurred. [4]
In October 2012 she established a committee on Standards in Reporting in MRI-targeted biopsy (START). [5] [ citation needed ] The recommendations included reporting histologic results of standard cores using Gleason scores and maximum core cancer length,as well as reporting the recruitment criteria,radiologist experience and population biopsy status of a particular trial. [5] [ citation needed ] She has worked on a combination of multi-parametric MRI and cognitive fusion transperineal biopsy,which can reduce the time taken diagnose and treat diseases. [6] [ citation needed ] She has found that using MRI can reduce the need for biopsies by 28%. [7] [8] [9] In 2019,her MRI protocols were approved by the National Institute for Health and Care Excellence (NICE),and incorporated into national guidance for the investigation of men suspected of having clinically localised prostate cancer. [10]
Moore has developed electronic psychometric patient-reported outcome measures to monitor men who have had radical prostatectomy. [11] Men who have this surgery can suffer from urinary leakage and difficulties with erections. The survey allows researchers to track their progress and share information with their surgical teams. [12] Moore has been among a group of researchers spread across six hospitals who have been investigating high-intensity focused ultrasound (HIFU) as a treatment for prostate cancer. Five years after treatment with HIFU the cancer survival rate is 100%,the same as for the more traditional methods of surgery and radiotherapy,but with fewer side-effects. [13]
She has been Head of Urology at University College London,within the Division of Surgical and Interventional Sciences since 2018. She was senior author on the Prostate Evaluation for Clinically Important Disease:Sampling Using Image Guidance or Not? (PRECISION) study comparing standard prostate biopsy and MRI-targeted biopsy. [11] [14] [15] [16]
In 2019 Moore was the first woman in the United Kingdom to be made a Professor of Urology. [1] Her research has been supported by Prostate Cancer UK,the Movember Foundation,the Cancer Vaccine Institute,the National Institute for Health Research,the European Association of Urology Research Foundation,the Wellcome Trust and the Department of Health. [2] [17]
